🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

BUBOLight®, a New Phototherapy Device for the Treatment of the Newborn's Jaundice

RecruitingNAAges any - 30 DaysAllUniversity Hospital, Lille
NCT04365998 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

About 50% of full-term newborns and 80% of premature infants develop jaundice which is due to hyperbilirubinemia. In the majority of cases, jaundice disappears naturally without treatment within three weeks of birth, but the bilirubin level may remain too high, which can lead to a serious neurological disease: kernicterus. To avoid this, a therapeutic management must be instituted, and in some cases, one or more phototherapy sessions (PT) may be prescribed. The aim of this trial is to evaluate the safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy BUBOLight® included two removable strips of luminous textile incorporating optical fibers. 10 newborns requiring phototherapy, will be illuminated during four hours in one session of PT Bilirubin levels is taken at the start of phototherapy H0 and Controls are made at H+6 hours.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * At time of birth, infant is \> 35 weeks gestation * Presence of jaundice confirmed by measurement of bilirubin (transcutaneous bilirubinometer) * Total bilirubinemia rate requiring phototherapy according to National Institute for Health and Clinical Excellence. * Weight ≥2.500kg * Judged in good health by the investigator following the clinical examination and the medical data (absence of perinatal asphyxia, antibiotic treatment, respiratory disorders) * Absence of fœto-maternal rhesus incompatibility or Kell Exclusion Criteria: * Newborn already treated with phototherapy * Febrile state with body temperature \> 37.8°C * Total bilirubinaemia level is equal or excess 100 μmol / L of the indication of phototherapy. * Patient whose jaundice is due to haemolysis, obstruction functional or anatomical. * Minor relative * Newborn requiring exchange transfusion * Newborn with congenital erythropoietic porphyria or a family history of porphyria. * Patient requiring treatment other than phototherapy
💊

What it tests

  • BUBOLight® Device
📍

Where

1 site
Hop Jeanne de Flandre Chu Lille
Lille, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy